ANDLicence and Supply Agreement • March 21st, 2003 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • New York
EX-10.6 3 d928233dex106.htm EX-10.6 EXECUTION COPY Date: 26 June 2003 ELAN CORPORATION, PLC. AND WATSON LABORATORIES, INC. AMENDED AND RESTATED LICENCE AND SUPPLY AGREEMENT (VERAPAMIL)Licence and Supply Agreement • May 5th, 2020 • New York
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Akers Biosciences, Inc.Licence and Supply Agreement • August 7th, 2013 • Akers Biosciences Inc
LICENCE AND SUPPLY AGREEMENT betweenLicence and Supply Agreement • January 24th, 2005 • Gentium S.p.A.
(Fiscal Code and Vat Code No. 02098100130), with legal offices in Italy at Plazza XX Settembre, no2, 22079 Villa Guardia (CO), acting through its Legal Representative Ms. Laura Iris Ferro, born in Milan on August 3rd, 1951, and domiciled for his office for the purposes of this agreement care of the offices of the Company (hereinafter referred to as "GENTIUM")
ContractLicence and Supply Agreement • March 3rd, 2014 • Endo Health Solutions Inc. • Pharmaceutical preparations
The confidential portions of this exhibit have been filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN ***.
OXFORD BIOMEDICA (UK) LIMITED and SYNCOPATION LIFE SCIENCES INC LICENCE AND SUPPLY AGREEMENTLicence and Supply Agreement • November 6th, 2023 • CARGO Therapeutics, Inc. • Biological products, (no disgnostic substances) • England and Wales
EXECUTION COPY London/090/075921-00001/RBF/MEXG: L_LIVE_EMEA1:13015405v3Licence and Supply Agreement • October 8th, 2013 • Akers Biosciences Inc • In vitro & in vivo diagnostic substances • England and Wales
TARO PHARMACEUTICALS INC. -and- INTELLIPHARMACEUTICS, CORP. LICENCE AND SUPPLY AGREEMENT Desvenlafaxine Extended-Release Tablets (50 mg and 100 mg desvenlafaxine succinate) FOR SALE IN CANADA LICENSE AND SUPPLY AGREEMENTLicence and Supply Agreement • February 6th, 2024 • Intellipharmaceutics International Inc. • Pharmaceutical preparations • Ontario
THIS AGREEMENT, made as of July 29, 2022 (the “Effective Date”) between Taro Pharmaceuticals Inc., having its offices at 130 East Road, Brampton, Ontario, Canada, L6T 1C1 (“Taro”), and Intellipharmaceutics, Corp., having its offices at 30 Worcester Road, Toronto, Ontario, Canada M9W 5X2 (“IPC”). Taro and IPC are herein sometimes referred to individually as a “Party” and collectively as the “Parties”.
Cabaletta Bio, Inc. 2929 Arch Street, Suite 600, Philadelphia, PA 19104, USA Attention: CEO To whom it may concern Amendment to Licence and Supply AgreementLicence and Supply Agreement • August 10th, 2023 • Cabaletta Bio, Inc. • Biological products, (no disgnostic substances)
LICENCE AND SUPPLY AGREEMENT by and between GALENA BIOPHARMA INC of 310 State Street, Suite 208, Lake Oswego, OR 97034, USA (“Galena”) and ABIC MARKETING LIMITED of Hateena 1, Industrial Park Hevel Modiin, POB 925, Shoham 60850, Israel (“Teva”)Licence and Supply Agreement • March 12th, 2013 • Galena Biopharma, Inc. • Pharmaceutical preparations • New York
WHEREAS Galena is in the process of developing the Product, as defined below, and the parties agree that in the event the Product is approved for marketing by the US Food and Drug Administration (“FDA”) and/or by the European Medicines Agency (“EMA”), Galena will be willing to provide Teva with the Registration Dossier in order to enable Teva and/or its Affiliates to obtain the required Marketing Authorization from the competent Regulatory Authorities and to promote, distribute, sell, market or otherwise commercialize the Product in the Territory subject to the terms and conditions of this Agreement;
